We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
+13.58%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$17B
AUM Growth
+$1.79B
Cap. Flow
-$229M
Cap. Flow %
-1.35%
Top 10 Hldgs %
33.75%
Holding
1,490
New
144
Increased
706
Reduced
317
Closed
73

Top Buys

Rank Stock Value
1
O icon
Realty Income
O
+$448M
2
AMT icon
American Tower
AMT
+$132M
3
HIW icon
Highwoods Properties
HIW
+$92.2M
4
WELL icon
Welltower
WELL
+$79.2M
5
PLD icon
Prologis
PLD
+$71.1M

Top Sells

Rank Stock Value
1
VER
VEREIT, Inc.
VER
+$434M
2
CONE
CyrusOne Inc Common Stock
CONE
+$386M
3
WY icon
Weyerhaeuser
WY
+$118M
4
HR icon
Healthcare Realty
HR
+$68.6M
5
VTR icon
Ventas
VTR
+$64.7M

Sector Composition

Rank Sector Weight
1 Real Estate 60.4%
2 Technology 9.49%
3 Consumer Discretionary 4.17%
4 Communication Services 4.01%
5 Financials 3.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
1251
Dyne Therapeutics
DYN
$4.15B
$2K ﹤0.01%
+150
New +$2.11K
EWTX icon
1252
Edgewise Therapeutics
EWTX
$4.28B
$2K ﹤0.01%
+144
New +$2.59K
FDMT icon
1253
4D Molecular Therapeutics
FDMT
$502M
$2K ﹤0.01%
+94
New +$2.3K
FULC icon
1254
Fulcrum Therapeutics
FULC
$241M
$2K ﹤0.01%
138
– –
LKFT
1255
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$2K ﹤0.01%
32
– –
HUMA icon
1256
Humacyte
HUMA
$168M
$2K ﹤0.01%
+301
New +$2.98K
JANX icon
1257
Janux Therapeutics
JANX
$912M
$2K ﹤0.01%
+121
New +$2.54K
KRON
1258
DELISTED
Kronos Bio
KRON
$2K ﹤0.01%
+164
New +$2.57K
LXRX icon
1259
Lexicon Pharmaceuticals
LXRX
$1.03B
$2K ﹤0.01%
+434
New +$2.11K
MRSN
1260
DELISTED
Mersana Therapeutics
MRSN
$2K ﹤0.01%
10
– –
NAUT icon
1261
Nautilus Biotechnolgy
NAUT
$132M
$2K ﹤0.01%
+362
New +$1.94K
NKTX icon
1262
Nkarta
NKTX
$152M
$2K ﹤0.01%
113
– –
NUVL
1263
DELISTED
Nuvalent
NUVL
$2K ﹤0.01%
+125
New +$2.79K
OCUL icon
1264
Ocular Therapeutix
OCUL
$1.83B
$2K ﹤0.01%
262
– –
ORIC icon
1265
Oric Pharmaceuticals
ORIC
$1.17B
$2K ﹤0.01%
135
– –
PHAT icon
1266
Phathom Pharmaceuticals
PHAT
$928M
$2K ﹤0.01%
+92
New +$2.17K
PLRX icon
1267
Pliant Therapeutics
PLRX
$65M
$2K ﹤0.01%
123
– –
PSNL icon
1268
Personalis
PSNL
$1.25B
$2K ﹤0.01%
152
– –
RYTM icon
1269
Rhythm Pharmaceuticals
RYTM
$7.31B
$2K ﹤0.01%
172
– –
SPRO icon
1270
Spero Therapeutics
SPRO
$68.9M
$2K ﹤0.01%
110
– –
STRO icon
1271
Sutro Biopharma
STRO
$386M
$2K ﹤0.01%
16
– –
TBPH icon
1272
Theravance Biopharma
TBPH
$873M
$2K ﹤0.01%
215
+95
+79% +$828
TKNO icon
1273
Alpha Teknova
TKNO
$266M
$2K ﹤0.01%
+82
New +$1.82K
TNYA icon
1274
Tenaya Therapeutics
TNYA
$160M
$2K ﹤0.01%
+120
New +$2.62K
TRML
1275
DELISTED
Tourmaline Bio
TRML
$2K ﹤0.01%
+12
New +$1.78K
49 50
51
52 53

Similar funds

SAM
Storebrand Asset Management Lysaker, Norway $34.8B AUM 25.49% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
VIA
Vanguard Investments Australia Victoria, Australia $34.6B AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Daiwa Securities Group's Q4 2021 Portfolio in Review

As of Q4 2021, Daiwa Securities Group held 1,490 positions worth $17B, up 12% from $15.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Daiwa Securities Group's Q4 2021 filing shows 144 new, 706 increased, 317 reduced and 73 closed positions. Its largest new stake was State Street SPDR Portfolio S&P 500 High Dividend ETF: 333,500 shares worth $14M. The largest sale was VEREIT, Inc., an estimated $434M.

By sector, the portfolio is most concentrated in Real Estate at 60% of assets, up from 56% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Daiwa Securities Group's largest Q4 2021 buy was State Street SPDR Portfolio S&P 500 High Dividend ETF: 333,500 shares worth $14M.
  • Daiwa Securities Group added most to Realty Income in Q4 2021, an estimated $448M increase.
  • Daiwa Securities Group's biggest Q4 2021 reduction was CyrusOne Inc Common Stock, cutting an estimated $386M.
  • Daiwa Securities Group fully exited VEREIT, Inc. in Q4 2021, selling an estimated $434M.
  • Daiwa Securities Group's ten largest holdings make up 34% of its $17B portfolio in Q4 2021.
  • Daiwa Securities Group opened 144 new positions and closed 73 in Q4 2021.
  • Daiwa Securities Group's portfolio value rose 12% quarter-over-quarter to $17B.

Based on Daiwa Securities Group's 13F filing for Q4 2021, filed 3 Feb 2022.